GeoVax Labs (NASDAQ:GOVX – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare GeoVax Labs to related businesses based on the strength of its dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.
Insider & Institutional Ownership
6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 0.2% of GeoVax Labs shares are owned by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares GeoVax Labs and its competitors gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| GeoVax Labs | $2.49 million | -$21.47 million | -0.18 |
| GeoVax Labs Competitors | $742.02 million | $10.89 million | -18.46 |
GeoVax Labs’ competitors have higher revenue and earnings than GeoVax Labs. GeoVax Labs is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares GeoVax Labs and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GeoVax Labs | N/A | -1,010.68% | -420.06% |
| GeoVax Labs Competitors | -12,516.26% | -215.91% | -31.70% |
Analyst Recommendations
This is a breakdown of current recommendations for GeoVax Labs and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GeoVax Labs | 1 | 1 | 1 | 0 | 2.00 |
| GeoVax Labs Competitors | 9920 | 15327 | 45725 | 1601 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 108.47%. Given GeoVax Labs’ competitors stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs has less favorable growth aspects than its competitors.
Volatility & Risk
GeoVax Labs has a beta of 3.85, meaning that its stock price is 285% more volatile than the S&P 500. Comparatively, GeoVax Labs’ competitors have a beta of -1.85, meaning that their average stock price is 285% less volatile than the S&P 500.
Summary
GeoVax Labs competitors beat GeoVax Labs on 10 of the 13 factors compared.
About GeoVax Labs
GeoVax Labs is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s research is based in part on modified vaccinia Ankara (MVA), a viral-vector platform designed to prompt immune responses, including through the presentation of virus-like particles. Its vaccine pipeline includes GEO-CM04S1, an investigational COVID-19 vaccine being studied in clinical trials, as well as programs targeting other infectious diseases. GeoVax also develops Gedeptin, an investigational cancer therapy designed to make tumor cells more susceptible to treatment.
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.
